Friday, December 15, 2017 10:23:38 AM
Sales of Glatopa, which is available only in 20 mg doses, have been most affected. Health insurers appear to prefer the generics because they’re cheaper, neurologists said.
One reason that Copaxone sales have held up better than Glatopa’s is that some neurologists said they were able to persuade health insurers or pharmacies not to switch to a generic.
https://multiplesclerosisnewstoday.com/2017/12/15/use-of-multiple-sclerosis-therapy-ocrevus-continues-to-rise/
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM